Pelthos Therapeutics Inc.

PTHSAMEX • USD
6.95 USD
↘ 0.20 (2.85%)🟢LIVE (AS OF 09:31 AM EST)
🟢Market: OPEN

PTHS is currently priced at $6.95. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, exceptional Return on Equity (1261.7%), a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. Valuation metrics suggest PTHS is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Nov 16, 2026.

Open?$7.12
High?$7.18
Low?$7.12
Prev. Close?$7.15
Volume?298
Avg. Volume?63.3K
VWAP?$7.13
Rel. Volume?0.00x
Bid / Ask
Bid?$3.00 × 200
Ask?$8.58 × 100
Spread?$5.58
Midpoint?$5.79
Valuation & Ratios
Market Cap?28.1M
Shares Out?3.9M
Float?1.6M
Float %?43.0%
P/E Ratio?N/A
P/B Ratio?-4.54
EPS?-$19.86
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Pelthos Therapeutics Inc is a biopharmaceutical company committed to commercializing safe and efficacious therapeutic products to help patients with unmet treatment burdens. The Company currently has three U.S. Food and Drug Administration (FDA) approved products in its commercial portfolio, in various stages of commercialization, including ZELSUVMITM, XEPI, and XEGLYZE. The company operates in two reporting segments: the sale, promotion, and commercialization of approved commercial products, the Commercial Operations segment, and research and development activities related to developing a novel and proprietary class of NaV blockers that target the body's peripheral nervous system; and supportive activities to expand the NITRICIL nitric oxide-based technology.
Employees
92
Market Cap
28.1M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2024-02-16
Address
4020 STIRRUP CREEK DRIVE
DURHAM, NC 27703
Phone: 919-908-2422
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-1/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
92
Short Sent.?
41
Piotroski F-Score?0/9Weak
Altman Z-Score?-1.90Distress
Confidence?40%Low
Full Fundamental Analysis →
Short InterestElevated
Short % of Float?9.62%Elevated
Short Interest?158.5K
Days to Cover?2.0
Free Float1.6M
Avg Daily Volume79.3K
Settlement Date2026-10-30
Financial Health
Current Ratio?1.78Adequate
Quick Ratio?1.10Adequate
Cash Ratio?0.56Adequate
Debt/Equity?-10.55Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
S&P
97
-4.54CHEAP▾
P/S?
Peers
100
S&P
95
0.55CHEAP▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.6CHEAP▾
EV/Sales?
Peers
100
S&P
84
1.48CHEAP▾
Returns & Efficiency
ROE?
Peers
50
S&P
97
1,261.7%STRONG▾
ROA?
S&P
3
-60.6%WEAK▾
Cash Flow & Enterprise
FCF?$-32561000
Enterprise Value?$75.7M
Fundamentals ratios updated end of day